Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Dr. Angela Yee-Moon Wang, The University of Hong Kong
Information provided by (Responsible Party):
Dr. Angela Yee-Moon Wang, The University of Hong Kong Identifier:
First received: October 4, 2011
Last updated: January 14, 2017
Last verified: January 2017
This is a pilot, prospective randomized controlled study with the primary objective to evaluate and compare medical treatment of SHPT, namely oral cinacalcet versus surgical treatment, that is, parathyroidectomy with forearm autografting, on the progression of coronary artery and valvular calcification in endstage renal disease patients over 12 months. The change in arterial stiffening and bone mineral density as well as nutritional status will be evaluated as secondary objectives of this study.

Condition Intervention
Kidney Failure
Secondary Hyperparathyroidism
Vascular Diseases
Drug: Cinacalcet
Procedure: Surgical total parathyroidectomy with forearm autografting

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Medical (Oral Cinacalcet) Therapy Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Study

Resource links provided by NLM:

Further study details as provided by Dr. Angela Yee-Moon Wang, The University of Hong Kong:

Primary Outcome Measures:
  • Change in coronary artery calcium score and heart valve calcium score [ Time Frame: 52 weeks ]

Secondary Outcome Measures:
  • Change in aortic pulse wave velocity [ Time Frame: 24 and 52 weeks ]
  • change in bone mineral density at forearm, spine and femur [ Time Frame: 52 weeks ]
  • change in left ventricular mass index [ Time Frame: 52 weeks ]
  • change in left ventricular volume and function [ Time Frame: 52 weeks ]
  • Quality of Life scores [ Time Frame: 52 weeks ]
  • change in lean muscle mass [ Time Frame: 52 weeks ]
  • change in handgrip strength [ Time Frame: 24 and 52 weeks ]
  • Change in subjective global assessment [ Time Frame: 24 and 52 weeks ]
  • change in resting energy expenditure [ Time Frame: 24 and 52 weeks ]
  • change in intact parathyroid hormone (iPTH) level [ Time Frame: 52 weeks ]
  • Change in parathyroid gland size [ Time Frame: 52 weeks ]
  • change in serum albumin [ Time Frame: 24 and 52 weeks ]
  • Change in serum calcium and phosphate [ Time Frame: 24 and 52 weeks ]
  • Change in alkaline phosphatase [ Time Frame: 24 and 52 weeks ]

Estimated Enrollment: 70
Study Start Date: May 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cinacalcet treatment
Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
Drug: Cinacalcet
oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
Other Name: Regpara
Active Comparator: Surgical total parathyroidectomy
Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
Procedure: Surgical total parathyroidectomy with forearm autografting
Surgical total parathyroidectomy with forearm autografting will be performed

Detailed Description:
Patients with severe secondary hyperparathyroidism (SHPT) are frequently complicated with vascular calcification. There is some suggestion that subtotal parathyroidectomy may reduce or stabilize vascular calcium scores in dialysis patients. Experimental data suggests that SHPT plays an important role in mediating uraemic arterial disease and that parathyroidectomy largely prevented the development of calcification. Cinacalcet has emerged as a novel therapy for the treatment of SHPT and has been shown to reduce the need for surgical parathyroidectomy. However, their effects on vascular and bone status have not been evaluatedand compared with parathyroidectomy.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ESRD patients on long-term peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels > 800pg/mL.
  2. Patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.
  3. Patients with age between 18 - 75 years.

Exclusion Criteria:

  1. Patients with background valvular heart disease
  2. Patients who are unfit for general anaesthesia
  3. Patients with acute myocardial infarction within recent two months
  4. Patients with poor general condition
  5. Patients with plans for living related kidney transplant within 1 year
  6. Patients with previous history of parathyroidectomy
  7. Patients with underlying malignancy
  8. Patients with hepatic dysfunction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01447368

Contact: Angela YM Wang, MD, PhD 22554949

Hong Kong
Queen Mary Hospital and Tung Wah Hospital Recruiting
Hong Kong, Hong Kong, 0000
Contact: Angela YM Wang, MD, PhD    852-22554949   
Principal Investigator: Angela YM Wang, MD, PhD         
Sub-Investigator: Wai-Kei Lo, FRCP         
Sponsors and Collaborators
The University of Hong Kong
Principal Investigator: Angela YM Wang, MD, PhD University of Hong Kong, Queen Mary Hospital
  More Information

Responsible Party: Dr. Angela Yee-Moon Wang, Honorary Associate Professor, The University of Hong Kong Identifier: NCT01447368     History of Changes
Other Study ID Numbers: CP-2015
Study First Received: October 4, 2011
Last Updated: January 14, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Dr. Angela Yee-Moon Wang, The University of Hong Kong:
chronic kidney disease
peritoneal dialysis
secondary hyperparathyroidism
vascular calcification

Additional relevant MeSH terms:
Neoplasm Metastasis
Vascular Diseases
Renal Insufficiency
Hyperparathyroidism, Secondary
Neoplastic Processes
Pathologic Processes
Cardiovascular Diseases
Parathyroid Diseases
Endocrine System Diseases
Kidney Diseases
Urologic Diseases
Cinacalcet Hydrochloride
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017